Edwards Lifesciences (EW) Issues Q2 Earnings Guidance

Edwards Lifesciences (NYSE:EW) issued an update on its second quarter earnings guidance on Tuesday morning. The company provided EPS guidance of $1.27-1.37 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.33. The company issued revenue guidance of $1.02-1.08 billion, compared to the consensus revenue estimate of $1.04 billion.Edwards Lifesciences also updated its FY 2019 guidance to $5.10-5.35 EPS.

Shares of NYSE EW traded up $2.71 during midday trading on Tuesday, reaching $180.98. The company’s stock had a trading volume of 1,502,762 shares, compared to its average volume of 1,325,963. The company has a current ratio of 2.61, a quick ratio of 1.92 and a debt-to-equity ratio of 0.19. Edwards Lifesciences has a fifty-two week low of $123.00 and a fifty-two week high of $197.86. The company has a market cap of $36.88 billion, a price-to-earnings ratio of 38.51, a PEG ratio of 2.31 and a beta of 0.91.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, April 23rd. The medical research company reported $1.32 earnings per share for the quarter, beating analysts’ consensus estimates of $1.22 by $0.10. Edwards Lifesciences had a net margin of 19.40% and a return on equity of 31.09%. The company had revenue of $993.00 million during the quarter, compared to the consensus estimate of $989.87 million. During the same period in the previous year, the business earned $1.22 earnings per share. The firm’s quarterly revenue was up 11.0% on a year-over-year basis. On average, equities research analysts forecast that Edwards Lifesciences will post 5.22 earnings per share for the current year.



EW has been the subject of a number of analyst reports. Bank of America upgraded shares of Edwards Lifesciences from a neutral rating to a buy rating and lifted their price target for the company from $180.00 to $190.00 in a research report on Friday, January 18th. Citigroup lifted their price target on shares of Edwards Lifesciences from $118.00 to $119.00 and gave the company a sell rating in a research report on Wednesday, January 2nd. Morgan Stanley boosted their price objective on shares of Edwards Lifesciences from $180.00 to $197.00 and gave the company an overweight rating in a research report on Monday, March 18th. Barclays boosted their price objective on shares of Edwards Lifesciences from $150.00 to $160.00 and gave the company an underweight rating in a research report on Monday, March 25th. Finally, Deutsche Bank started coverage on shares of Edwards Lifesciences in a research report on Wednesday, January 2nd. They set a hold rating and a $164.00 price objective for the company. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have given a buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $182.29.

In other news, VP Larry L. Wood sold 6,716 shares of the company’s stock in a transaction on Monday, February 4th. The shares were sold at an average price of $169.10, for a total transaction of $1,135,675.60. Following the completion of the transaction, the vice president now directly owns 35,224 shares in the company, valued at $5,956,378.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Michael A. Mussallem sold 32,800 shares of the company’s stock in a transaction on Tuesday, February 12th. The stock was sold at an average price of $176.90, for a total transaction of $5,802,320.00. Following the transaction, the chief executive officer now owns 75,926 shares of the company’s stock, valued at $13,431,309.40. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 114,328 shares of company stock valued at $20,121,304. Company insiders own 1.63% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Edwards Lifesciences (EW) Issues Q2 Earnings Guidance” was originally published by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://dakotafinancialnews.com/2019/04/24/edwards-lifesciences-ew-issues-q2-earnings-guidance.html.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Further Reading: Moving Average – How it Helps Investors in Stock Selection

Earnings History and Estimates for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.